SecBot SecBot
144 ·Filed Jul 1, 2026

AXSM

Axsome Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed4mo ago SEC0001958244-26-000417
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

The pre-arranged 10b5-1 plan limits signaling value; monitor for actual execution in coming days. No material read-through to fundamentals given the plan's adoption date.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$244.31
T+0 close · Jul 1, 2026 · via day close
Latest settled
−19.76%
T+60 · $196.03
Vs SPY
−22.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 2 $244.31entry
  2. T+1 · 4mo ago −0.70%α −1.57% · $242.60
  3. T+5 · 4mo ago +1.90%α +0.97% · $248.95
  4. T+20 · 4mo ago −3.96%α −3.54% · $234.64
  5. T+60 · 7w ago −19.76%α −22.77% · $196.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Herriot Tabuteau filed a Form 144 to sell 49,666 common shares (approx. $11.9M) under a Rule 10b5-1 plan adopted on 3/10/2026. The sale is pre-arranged and part of a planned diversification, reducing concern of opportunistic insider selling.

Key Facts

  • CEO Herriot Tabuteau intends to sell 49,666 shares of common stock (~$11.95M).
  • Sale is under a 10b5-1 trading plan adopted on 3/10/2026.
  • Shares acquired as compensation (stock options) on 3/15/2017.
  • Recent insider selling (30d): 6 sells totaling $20.3M.

Financial Impact

~$11.95M in potential selling pressure, but pre-planned and small relative to $12.6B market cap (0.09%).

dilutioninsider selling

Risk Factors

  • Potential overhang if large sell orders hit market, though planned nature mitigates signal.
  • CEO reducing stake may reflect personal diversification, not company outlook.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001958244-26-000417
Document: 0001958244-26-000417-index.html0001958244-26-000417
Document: 0001958244-26-000417.txt0001958244-26-000417

Track record

26 reports on AXSM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Viewing Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 7h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 1, 2026